Bradley E. Chipps

Bradley E. Chipps's AcademicInfluence.com Rankings

Bradley E. Chipps

Philosophy

#7569

World Rank

#10803

Historical Rank

Logic

#4619

World Rank

#5934

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Bradley E. Chipps's Degrees

Doctorate Medicine University of California, Davis

Why Is Bradley E. Chipps Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bradley E. Chipps's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Standards and indications for cardiopulmonary sleep studies in children. American Thoracic Society. (1996) (1175)
Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy (2015) (876)
Oral Immunotherapy for Treatment of Egg Allergy in Children (2013) (370)
Reduction of serum testosterone levels during chronic glucocorticoid therapy. (1986) (368)
Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. (2004) (299)
Long-term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma (2007) (218)
Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. (2014) (192)
Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. (2012) (183)
Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. (2007) (169)
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. (2009) (167)
Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema (2011) (161)
Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. (2005) (157)
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. (2019) (147)
A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy (2017) (145)
Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. (2010) (116)
Section on Allergy and Immunology (2011) (113)
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. (2017) (112)
Test for respiratory and asthma control in kids (TRACK): a caregiver-completed questionnaire for preschool-aged children. (2009) (112)
Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma. (2009) (109)
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma (2017) (109)
Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma. (2020) (104)
Intermittent Inhaled Corticosteroids in Infants With Episodic Wheezing (2007) (104)
The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. (2010) (99)
The Role of Nebulized Therapy in the Management of COPD: Evidence and Recommendations (2012) (99)
High-resolution inspiratory and expiratory CT in older children and adults with bronchopulmonary dysplasia. (1999) (97)
Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. (2016) (94)
Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. (2006) (89)
Gender Differences in IgE-Mediated Allergic Asthma in the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) Study (2006) (87)
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma (2019) (83)
Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. (2014) (82)
Economic burden of impairment in children with severe or difficult-to-treat asthma. (2011) (81)
Genomewide Association Between GLCCI1 and Response to Glucocorticoid Therapy in Asthma (2012) (80)
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. (2018) (80)
A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. (1981) (76)
Sudden infant death syndrome in infants evaluated by apnea programs in California. (1986) (73)
Association of Improved Air Quality With Lung Development in Children (2015) (70)
Rapid detection of gram-negative bacteriuria by use of the Limulus endotoxin assay. (1973) (66)
Clinical Tools to Assess Asthma Control in Children (2017) (65)
Diagnosis and treatment of anaphylactic reactions to Hymenoptera stings in children. (1980) (63)
T2-"Low" Asthma: Overview and Management Strategies. (2020) (59)
Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. (2017) (58)
CONTROL OF EXPOSURE TO MITE ALLERGEN AND ALLERGEN-IMPERMEABLE BED COVERS FOR ADULTS WITH ASTHMA (2004) (56)
Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort (2012) (53)
Test for Respiratory and Asthma Control in Kids (TRACK): clinically meaningful changes in score. (2011) (51)
Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. (2009) (48)
Improvement in quality of life with omalizumab in patients with severe allergic asthma (2006) (48)
Noninvasive evaluation of ventricular function in cystic fibrosis. (1979) (48)
Detection of pulmonary aspiration in infants and children with respiratory disease: concise communication. (1980) (45)
A LONGITUDINAL, POPULATION-BASED, COHORT STUDY OF CHILDHOOD ASTHMA FOLLOWED TO ADULTHOOD (2004) (45)
Longitudinal Validation of the Test for Respiratory and Asthma Control in Kids in Pediatric Practices (2011) (43)
Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. (1993) (43)
Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. (2012) (43)
IgA deficiency, recurrent pneumonias, and bronchiectasis. (1978) (42)
More than a decade follow‐up in patients with severe or difficult‐to‐treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II (2017) (42)
Dose counting and the use of pressurized metered-dose inhalers: running on empty. (2006) (40)
Cough in the pediatric population. (2010) (40)
Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. (2009) (36)
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis. (2020) (35)
Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR (2010) (35)
Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. (2019) (35)
High‐frequency jet ventilation in children with the adult respiratory distress syndrome complicated by pulmonary barotrauma (1993) (33)
Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists. (2006) (32)
Racial Disparities in Asthma-Related Health Outcomes in Children with Severe/Difficult-to-Treat Asthma. (2019) (32)
The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma. (2018) (31)
Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States (2011) (30)
More Than a Decade Follow-up in Severe or Difficult-to-Treat Asthma : 1 TENOR II 2 (2017) (30)
Allergy Testing in Childhood: Using Allergen-Specific Ige Tests (2017) (30)
Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses (2014) (29)
EFFECTS OF REDUCING OR DISCONTINUING INHALED BUDESONIDE IN PATIENTS WITH MILD ASTHMA (1995) (29)
Challenges in the treatment of asthma in children and adolescents. (2018) (29)
Nocturnal oxygen saturation in normal and asthmatic children. (1980) (28)
Determinants of asthma and its clinical course. (2004) (28)
Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. (2017) (27)
Assessment and treatment of acute asthma in children. (2005) (26)
Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. (2017) (25)
Bronchial thermoplasty: a review of the evidence. (2016) (25)
The burden of exacerbations in mild asthma: a systematic review (2020) (25)
Effect of theophylline and terbutaline on immediate skin tests. (1980) (24)
Dupilumab improves clinical outcomes in patients with asthma and perennial allergic rhinitis. (2020) (24)
Update in Pediatric Anaphylaxis (2013) (23)
Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. (2004) (22)
AR101 Oral Immunotherapy for Peanut Allergy (2019) (22)
Update on the utility of corticosteroids in acute pediatric respiratory disorders (2015) (22)
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life. (2018) (22)
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. (2017) (21)
Pulmonary Hemangiomas of Infancy and Childhood: Report of Two Cases and Review of the Literature (2002) (21)
Symptoms and perception of airway obstruction in asthma: clinical implications for use of reliever medications. (2019) (21)
Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma. (2019) (21)
What Are the Determinates of Asthma Control? (2006) (21)
Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. (2012) (20)
Severe Asthma in Primary Care: Identification and Management. (2018) (19)
Phenotypic Expressions of Childhood Wheezing and Asthma: Implications for Therapy (2011) (19)
Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy-An NIAID/AHRQ Workshop. (2019) (19)
Office-based objective measures in childhood asthma. (2006) (19)
Comparison of asthma exacerbations in pediatric and adult patients with severe or difficult-to-treat asthma. (2009) (19)
Evaluation of Olopatadine Hydrochloride Nasal Spray, 0.6%, Used in Combination with an Intranasal Corticosteroid in Seasonal Allergic Rhinitis (2010) (17)
Economic Burden of Impairment in Children with Severe or Difficult-to-Treat Asthma (2010) (17)
Once- vs Twice-Daily Budesonide/Formoterol in 6- to 15-Year-Old Patients With Stable Asthma (2010) (17)
The Asthma Controller Step-down Yardstick. (2019) (16)
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. (2022) (16)
Continuous positive airway pressure in hemidiaphragmatic paralysis. (1980) (15)
Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters. (2011) (15)
Infants undergoing pyloromyotomy are not at risk for postoperative apnea (1999) (15)
Inhaled corticosteroid therapy for patients with persistent asthma: learnings from studies of inhaled budesonide. (2009) (15)
Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. (2020) (15)
Non-candidal infections in children with chronic mucocutaneous candidiasis. (1979) (14)
Evaluation of infants and children with refractory lower respiratory tract symptoms. (2010) (14)
Immediate (IgE-mediated) skin testing in the diagnosis of allergic disease. (1978) (14)
Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes (2018) (14)
Associations Between Individual Characteristics and Blood Eosinophil Counts in Adults with Asthma or COPD. (2019) (14)
Respiratory papillomas: Presentation before six months (1990) (13)
Management of Food Allergy in the School Setting (2016) (13)
2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges. (2021) (12)
Evaluating omalizumab persistency of response after long-term therapy (XPORT) (2014) (12)
Prevention of Hereditary Angioedema Attacks With a Subcutaneous C1 Inhibitor (2017) (12)
Systemic reaction to omalizumab. (2006) (12)
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics (2021) (12)
Rapid Detection of Gram-Negative Bacteriuria by Use of the Limulus Endotoxin Assay (1973) (11)
Asthma in infants and children. (2008) (10)
The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results (2020) (10)
Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II. (2020) (10)
A Comprehensive Analysis of the Stability of Blood Eosinophil Levels (2021) (10)
Vortran High Output Extended Aerosol Respiratory Therapy (HEART) for Delivery of Continuously Nebulized Terbutaline for the Treatment of Acute Bronchospasm (1990) (10)
Tiotropium in Children and Adolescents With Asthma. (2019) (10)
Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. (2016) (10)
Effect of Inhaled Glucocorticoids in Childhood on Adult Height (2013) (10)
142. The effects of oral theophylline and terbutaline on skin tests and histamine release (1978) (9)
Antihistamine treatment for allergic rhinitis: different routes, different outcomes? (2009) (9)
ENVIRONMENTAL EXPOSURE TO ENDOTOXIN AND ITS RELATION TO ASTHMA IN SCHOOL-AGE CHILDREN (2003) (8)
Inhaled Combined Budesonide-Formoterol as Needed in Mild AsthmaAs Needed Budesonide-Formoterol Versus Maintenance Budesonide in Mild Asthma (2018) (7)
Severe Asthma in Children (2017) (7)
Biologic and Maintenance Systemic Corticosteroid Therapy Among U.S., Subspecialist-treated Severe Asthma Patients. (2020) (7)
Omalizumab significantly improves quality of life in patients with severe persistent asthma (2005) (7)
Relative efficacy and safety of inhaled corticosteroids in patients with asthma (2020) (7)
A Review of the Role of Inhaled Corticosteroids in the Treatment of Acute Asthma (2001) (6)
Clinical comparison of Gentle-Haler Actuator and Aerochamber Spacer for Metered Dose Inhaler (MDI) use by asthmatics. (1992) (6)
Risk Factors Associated With Persistent Airflow Limitation in Severe or Difficult-to-Treat Asthma * Insights From the TENOR Study June (2007) (6)
LONG TERM EFFECTS OF A LONG-ACTING B2-ADRENORECEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSWENESS IN PATIENTS WITH MILD ASTHMA (1994) (6)
Patient-Reported Outcomes among Omalizumab and Salmeterol/Fluticasone Combination Therapy Patients (2009) (6)
Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma (2006) (6)
Omalizumab in Asthma With Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. (2021) (6)
Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology. (2019) (6)
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study (2021) (5)
Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma (2021) (5)
Sequelae of H. influenzae type b empyema. (1979) (5)
Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. (2020) (5)
Test for respiratory and asthma control in kids (TRACK): a validated control tool for preschool-aged children. (2014) (5)
Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma. (2020) (5)
Relative efficacy and safety of inhaled corticosteroids in asthma patients: systematic review and network meta-analysis. (2020) (4)
The Added Burden of Allergen Sensitization among Children with Severe or Poorly-Controlled Asthma. (2020) (4)
Harmonization of Terminology for Tolerated and Reactive Dose in Food Allergy Immunotherapy. (2019) (4)
Do weather conditions change pulmonary function of asthmatics at summer camp? (1984) (4)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma (2018) (4)
Assessing Construct Validity of the Asthma Impairment and Risk Questionnaire Using a 3-month Exacerbation Recall. (2022) (4)
Diurnal variation of air and helium-oxygen flow-volume curves in asthmatic children. (1982) (4)
Targeted IgE Therapy for Patients With Moderate to Severe Asthma. (2004) (4)
RapidDetection ofGram-Negative Bacteriuria byUseoftheLimulus Endotoxin Assay (1973) (4)
Budesonide Inhalation Suspension Reduces the Need for Emergency Intervention in Pediatric Asthma: A Named‐Patient Case Series (2003) (4)
Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Asthma Control, Quality of Life and Lung Function Outcomes (2018) (4)
Dupilumab Consistently Improves Rhinoconjunctivitis‐Specific Health‐Related Quality of Life in Patients With Uncontrolled, Moderate‐to‐Severe Asthma and Comorbid Allergic Rhinitis: Results from the Phase 3 LIBERTY ASTHMA QUEST Study: 304 (2019) (3)
Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration: 307 (2019) (3)
Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations (2018) (3)
Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: the TYREE study. (2021) (3)
A Multicenter, Randomized, Controlled Trial of Dexamethasone for Bronchiolitis (2008) (3)
Biologics for Asthma and Allergic Skin Diseases in Children (2021) (3)
A CYSTIC FIBROSIS MUTATION ASSOCIATED WITH MILD LUNG DISEASE (1996) (3)
EFFECT OF OMALIZUMAB ON PERIPHERAL BLOOD EOSINOPHILS IN CHILDREN WITH MODERATE-SEVERE PERSISTENT ALLERGIC ASTHMA (2009) (3)
A Physiologic Assessment of Segmental Bronchial Atresia1–3 (2015) (3)
Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations. (2022) (3)
Theophylline and the danger of differing absorption capabilities (1977) (3)
Single bone involvement in congenital syphilis (1976) (3)
Spontaneous resolution of multilobar atelectasis secondary to fibrinous mediastinitis. (1982) (3)
Biologic Therapies of Immunologic Diseases. (2017) (3)
Dupilumab Suppresses Type 2 Biomarkers in Asthma Patients With and Without Comorbid Chronic Rhinosinusitis With or Without Nasal Polyposis (CRS/NP): Post Hoc Analysis of LIBERTY ASTHMA QUEST: 296 (2019) (3)
Fractional exhaled nitric oxide of at least 100 ppb and implications for future asthma research. (2014) (3)
Determinants of lung function improvement with omalizumab in adults with allergic asthma. (2020) (3)
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF NEBULIZED EPINEPHRINE IN INFANTS WITH ACUTE BRONCHIOLITIS (2004) (3)
Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US CHRONICLE study (2022) (2)
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. (2010) (2)
Update on the 2007 National Asthma Education and Prevention Program (2008) (2)
Approach to the difficult pediatric asthmatic. (1999) (2)
Renal involvement in systemic diseases in childhood. (1976) (2)
Impact of Baseline IgE levels on Exacerbations and Asthma Symptom Control After Omalizumab Initiation (2018) (2)
Response to Omalizumab Observed Over Wide Range of Blood Eosinophil Levels (2018) (2)
Variability in asthma severity/control in pediatric asthma patients previously receiving short-acting beta2-agonists (2004) (2)
To the editor: Reply to Dr. Bisgaard (2004) (2)
Daily Versus As-Needed Corticosteroids for Mild Persistent Asthma (2006) (2)
Managing chronic subdural hematomas and effusions in infants: a continuing dilemma. (1974) (2)
Baseline characteristics of a large cohort of severe or difficult to treat asthma subjects from the epidemiology and natural history of asthma: Outcomes and treatment regimens (TENOR) study (2002) (2)
A physiologic assessment of segmental bronchial atresia. (1980) (2)
Dupilumab Efficacy in Patients with Uncontrolled or Oral Corticosteroid-Dependent Allergic and Non-allergic Asthma. (2022) (2)
Chapter 6 – How Do You Diagnose Asthma in the Child? (2008) (2)
EFFICACY OF ADDING NEBULIZED IPRATROPIUM BROMIDE TO NEBULIZED ALBUTEROL THERAPY IN ACUTE BRONCHIOLITIS (1994) (2)
Decreased Exacerbations and Improvement in Asthma Symptom Control in Asthma COPD Overlap Treated With Omalizumab: Data From the Prospero Cohort Study (2017) (2)
Allergy, Serum IgE, and Lung Function in Children and Adolescents With Severe or Difficult-to-Treat Asthma (2007) (2)
Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects (2017) (2)
Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects (2017) (2)
Asthma as a Risk Factor for Invasive Pneumococcal Disease (2006) (2)
Responder Analysis Evaluating the Long-term Treatment of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) in Patients With Moderate to Severe Asthma With Versus Without Fixed Airflow Obstruction (FAO) (2013) (2)
Abstracts from the North American Rhinology & Allergy Conference, February 3, 2011, Puerto Rico (2011) (1)
Assessing the Asthma Impairment and Risk Questionnaire’s ability to predict exacerbations (2021) (1)
Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections (2014) (1)
Dose counting and use of short-acting beta-agonist inhalers in emergency department patients with asthma exacerbation. (2018) (1)
Real-World Biologic Medication Use in a Diverse Population of US, Specialist-Treated Adults with Severe Asthma -Results of CHRONICLE Study (2019) (1)
Stability of eosinophil classifications using common cut‐points over time: 28 (2019) (1)
Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhaler in Patients With Mild to Moderate Asthma With and Without Fixed Airflow Obstruction (2012) (1)
P104 TOTAL NASAL SYMPTOM SCORE IMPROVEMENT WITH BENRALIZUMAB FOR PATIENTS WITH SEVERE, EOSINOPHILIC ASTHMA (2019) (1)
Baseline Asthma Impairment and Risk Questionnaire (AIRQ™) Control Level is Associated with Future Risk of Exacerbations (2021) (1)
811 COURSE AND SEOUELAE OF H. INFLUENZAE B (HIB) EMPYEMA (1978) (1)
Influence of Key Clinical Baseline Characteristics on Benralizumab Response for Patients with Severe, Uncontrolled Asthma and Moderate Blood Eosinophilia (2020) (1)
Targeted interventions for difficult-to-treat asthma (2007) (1)
Faculty of 1000 evaluation for Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. (2012) (1)
Review of efficacy of ciclesonide for the treatment of asthma in children. (2021) (1)
Demographic Characteristics, Comorbidities, and Exacerbation Frequency Among Patients Enrolled in the Chronicle Study: A Real‐World, Prospective, Observational Study of US, Subspecialist‐Treated Adults with Severe Asthma: L27 (2019) (1)
MEDICAL PROGRESS OFFICE-BASED OBJECTIVE MEASURES IN CHILDHOOD ASTHMA (2006) (1)
692 VENOM IMMUNOTHERAPY FOR INSECT HYPERSENSITIVITY (1978) (1)
THE EFFECT OF AGE ON BRONCHODILATOR RESPONSIVENESS (1994) (1)
Diagnosis of Asthma in Preschool-Age Children (2014) (1)
Characteristics by Provider Subspecialty of Patients Enrolled in the CHRONICLE Study: A Real-World, Prospective, Observational Study of US, Subspecialist-Treated Adults with Severe Asthma (2019) (1)
Long-term outcomes from a pediatric subgroup of TENOR I: 10 years follow up (2017) (1)
Montelukast, A Leukotriene-Receptor Antagonist, For the Treatmentof Mild Asthma and Exercise-Induced Bronchoconstriction (1999) (1)
CHEMOSENSITIVITY AND PERCEPTION OF DYSPNEA IN PATIENTS WITH A HISTORY OF NEAR-FATAL ASTHMA (1995) (1)
Carbon in Airway Macrophages and Lung Function in Children (2007) (1)
Chronic cough: Watch for "red flags" (2015) (1)
GENETIC SUSCEPTIBILITY TO ASTHMA— BRONCHIAL HYPERRESPONSIVENESS COINHERITED WITH MAJOR GENE FOR ATOPY (1996) (1)
Skin testing and IgE levels in patients with severe or difficult-to-treat asthma (2005) (1)
P062 BENRALIZUMAB REAL-WORLD EFFECTIVENESS ON EXACERBATIONS AMONG US SPECIALIST-TREATED PATIENTS WITH SEVERE ASTHMA: DATA FROM CHRONICLE (2021) (1)
The Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQTM) and Health-Related Quality of Life (2020) (1)
Safety of ciclesonide in children with asthma: A review of randomized controlled trials. (2021) (1)
Clinically Significant Improvements in Asthma Patient-Reported Outcomes: Results from the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study (2017) (1)
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. (2018) (1)
Family History, Dust Mite Exposure in Early Childhood, and Risk for Pediatric Atopy and Asthma (2005) (1)
Acute asthma: The basics of assessment and treatment (2002) (1)
Evaluation of the Impairment Domain Components of the NHLBI Guidelines in Classifying Asthma Control and Predicting Future Asthma Exacerbations (2010) (1)
Characteristics of US, Subspecialist-Treated Adults with Severe Asthma Receiving and Not Receiving Therapy with Biologic Medications in the CHRONICLE Study (2019) (1)
Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II Cohort. (2021) (1)
The Bela Schick Lecture: if you don't know where you are going, you may end up somewhere else. (2015) (1)
P235 Budgetary impact model on a medicare plan adopting short-acting beta-agonist inhalers with integrated dose counters (2017) (0)
From the Pages of Allergy Watch. (2020) (0)
A PROSPECTIVE RANDOMIZED STUDY OF CONTINUOUS VERSUS INTERMITTENT NEBULIZED ALBUTEROL FOR SEVERE STATUS ASTHMATICUS IN CHILDREN (1995) (0)
P230 Long-term assessment of the burden of atopic sensitization in patients with severe/difficult-to-treat asthma (2017) (0)
Feasibility of Using Treatment Response Thresholds for Lung Function and Asthma Symptom Variables As Indicators of Asthma Control in Patients with Moderate to Severe Asthma (2016) (0)
Noninvasive evaluation in cystic fibrosis of ventricular function (1979) (0)
EFFECTS OF OMALIZUMAB ON MARKERS OF TYPE 2 INFLAMMATION: RESULTS FROM THE EXTRA STUDY (2018) (0)
Effects of Budesonide/Formoterol (BUD/FM) Deliverd By Pressurized Metered-Dose Inhaler (pMDI) on Symptoms In African Americans and Caucasians With Moderate and Severe Asthma With and Without Fixed Airway Obstruction (FAO) (2014) (0)
Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma (SEA): Subgroup Analyses of Patients Using Maintenance Oral Corticosteroids (OCS) Prior to Treatment Initiation (2020) (0)
An Analysis of Type 2 Biomarkers in TENOR II (2018) (0)
CONFIRMATORY CROSS-SECTIONAL VALIDATION OF THE ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE (AIRQ) (2020) (0)
Phenotypes Determined By Cluster Analysis In Patients With Severe Or Difficult-To-Treat Asthma In The TENOR Cohort (2012) (0)
NOT RUNNING ON EMPTY (2006) (0)
Demographic Characteristics and Laboratory Biomarker Testing of Patients Receiving Individual Biologic Therapies for Severe Asthma in the United States (2021) (0)
From the Pages of Allergy Watch: December 2019. (2019) (0)
Health-related Quality of Life and Productivity Among a Real-World Cohort of Severe Asthma Patients in the United States (2020) (0)
BIOLOGIC MEDICATIONS FOR SEVERE ASTHMA ARE EFFECTIVE IN THE REAL-WORLD, INCLUDING IN SUBGROUPS NOT STUDIED IN RANDOMIZED TRIALS (2021) (0)
Do Fish Oil Supplements During Pregnancy Prevent Asthma ? (2018) (0)
Recent advances in asthma. (2018) (0)
Asthma Control and Risk of Future Asthma Exacerbations: Evaluation of the Impairment Domain of the NHLBI Guidelines in the TENOR Cohort (2009) (0)
P205 SWITCH FROM OMALIZUMAB TO MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: EFFECT OF WEIGHT AND BMI (2020) (0)
Inhaled nitric oxide for acute asthma. Authors' reply (2006) (0)
Faculty Opinions recommendation of Daily or intermittent budesonide in preschool children with recurrent wheezing. (2011) (0)
Effects Of Long-Term Treatment With Budesonide/Formoterol (BUD/FM) Delivered By Pressurized Metered-Dose Inhaler (pMDI) On Symptoms In African-American and Caucasian Patients With Moderate To Severe Asthma With and Without Fixed Airway Obstruction (FAO) (2014) (0)
Continuous Intravenous Terbutaline for Pediatric StatusAsthmaticus (1999) (0)
Asthma Yardstick (2017) (0)
TENOR Study Difficult-to-Treat Asthma: Insights From the Airflow Limitation in Severe or Risk Factors Associated With Persistent (2007) (0)
P224 REAL-WORLD EVIDENCE OF IMPROVED PATIENT OUTCOMES WITH RESLIZUMAB IN ADULTS WITH SEVERE EOSINOPHILIC ASTHMA (SEA) (2019) (0)
Post Hoc Analysis of a Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) Study: Asthma Control and Study Withdrawal in Patients With Mild to Moderate Asthma With Versus Without Fixed Airflow Obstruction Defined Using 2 Different Criteria (2012) (0)
PREDICTORS OF A FUTURE SEVERE ASTHMA EXACERBATION AFTER A DECADE FOLLOW-UP: RESULTS FROM TENOR II (2018) (0)
Dupilumab in Children With Uncontrolled Moderate-to-Severe Asthma (2022) (0)
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. Reply. (2022) (0)
A Comparison of Active and Simulated Chiropractic Manipulation asAdjunctive Treatment for Childhood Asthma (1999) (0)
Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States (2021) (0)
Faculty Opinions recommendation of Decision making in patients with pulmonary nodules. (2012) (0)
Faculty Opinions recommendation of Vitamin D and atopy and asthma phenotypes in children: a longitudinal cohort study. (2012) (0)
APPLICATION OF ORAL IMMUNOTHERAPY (OIT) CLINICAL TRIAL ENDPOINTS TO A REAL-WORLD SETTING (2018) (0)
Zileuton for the Prophylaxis and Chronic Treatment of Asthma (2008) (0)
From the pages of AllergyWatch®: February 2021. (2020) (0)
Pediatric Dilemmas: Allergy and Beyond (2013) (0)
Evaluating Performance of the Asthma Impairment and Risk Questionnaire (AIRQ™) in Primary and Specialty Care (2021) (0)
Effect of Reversibility and Eosinophils on Lung Function Improvement with Omalizumab Treatment: Pooled Analyses in Patients with Moderate or Severe Allergic Asthma (2019) (0)
Detectionof PulmonaryAspirationin InfantsandChildrenwith Respiratory Disease:ConciseCommunication (2006) (0)
Responder Analysis Evaluating the Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) in Patients with Moderate to Severe Asthma with Versus without Fixed Airflow Obstruction (FAO) (2013) (0)
that will be most beneficial. Further studies would benefit from a larger sample, more precise characterization of asthma (to rule out other illnesses that can cause elevated FeNO levels, such as eosin- ophilic bronchitis), and an assessment of medication adherence. (2014) (0)
P060 ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE (AIRQ) AT BASELINE PREDICTS 12-MONTH HEALTH-RELATED QUALITY OF LIFE (HRQOL) (2021) (0)
Preferences in terminology used to describe oral immunotherapy varies based on physician utilization (2020) (0)
REPRODUCIBILITY OF THE ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE (AIRQ) (2021) (0)
From pages of Allergy Watch: April-2020. (2019) (0)
From the Pages of Allergy Watch. (2020) (0)
Novel epinephrine auto-injector (NEA): sharps injury prevention validation and comparable analysis with EpiPen and Twinject. (2011) (0)
Real-World Evidence of Reductions in Health Resource Utilization (HRU) and Improved Efficacy Outcomes Associated with Reslizumab Treatment in Adults with Severe Eosinophilic Asthma (SEA) in the United States (2020) (0)
Clinical Features and Anaphylaxis in Children With Cold Urticaria (2005) (0)
Faculty Opinions recommendation of Effect of vitamin D and inhaled corticosteroid treatment on lung function in children. (2012) (0)
Association Between Severity of Asthma Exacerbations and Asthma-Related Quality of Life in Patients With Severe or Difficult-to-Treat Asthm (2011) (0)
Do Weather Conditions Asthmatics Change Pulmonary Function of at Summer Camp (1984) (0)
Long-term Effects of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) in African-American Patients With Moderate to Severe Asthma: Responder Analysis in Patients With Versus Without Fixed Airflow Obstruction (FAO) (2013) (0)
From the Pages of AllergyWatch. (2022) (0)
In the UnitedStates,wesupportthe approachrecommended by the US Rhinitis Practice Parameters, which recommends NAH as first-line therapy. 2 It is our unanimous clinical experience that these medications are useful as a primary therapy. (2016) (0)
Clinical characteristics and disease control of US asthma patients treated in specialty clinics (2020) (0)
Biomarkers Associated with Response in Patients Initiating Omalizumab: Baseline Levels Among Patients in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study (2016) (0)
Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. (2023) (0)
Are Inhaled Corticosteroids and Inhaled Corticosteroids/Long-acting β-Agonist of Use in Acute Asthma: an Update on Evidence (2019) (0)
Poster 74: A Multisite Patient Perception Study of Olopatadine 0.2% Compared To Epinastine 0.05% in Patients With Allergic Conjunctivitis (2008) (0)
Real-world Evidence of Improved Patient Outcomes With Reslizumab in Non-exacerbating Patients With Severe Eosinophilic Asthma (SEA): A Subgroup Analysis (2020) (0)
Lessons learned from the epidemiology and natural history of asthma: Outcomes and treatment regimens (TENOR) (2011) (0)
O018 Asthma exacerbations and triggers in children with severe/difficult-to-treat asthma: Impact on quality of life (2016) (0)
Phase III Evaluation of the Efficacy and Safety of PT027 (Budesonide/Albuterol pMDI) Compared to Placebo pMDI on Exercise-Induced Bronchoconstriction in Adult and Adolescent Subjects with Asthma: the TYREE Study (0)
From the Pages of Allergy Watch. (2021) (0)
P208 Contribution of obesity to disease burden in children with severe or difficult-to-treat asthma (2017) (0)
Recent advances in our understanding of the environment's role in allergy. (2018) (0)
P223 EVALUATING PERFORMANCE OF THE ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE (AIRQ™) AT 3-MONTH INTERVALS (2020) (0)
Anaphylaxis: A 7-Year Follow-up Survey of 46 Children (2005) (0)
EDS-FLU (EXHALATION DELIVERY SYSTEM WITH FLUTICASONE) BENEFITS ON NASAL POLYP DISEASE RELATIVE TO MONOCLONAL ANTIBODIES (2018) (0)
Identifying Patients for Self-Administration of Omalizumab (2022) (0)
From the Pages of Allergy Watch. (2021) (0)
in Pediatric Practices Longitudinal Validation of the Test for Respiratory and Asthma Control in Kids (2011) (0)
P120 Burden of severe or poorly-controlled asthma in school-age children: healthcare use and allergic co-morbidities (2016) (0)
Correction to: Identifying Patients for Self-Administration of Omalizumab (2022) (0)
High medication usage in a large cohort of patients with severe or difficult-to-treat asthma* (2003) (0)
From the Pages of AllergyWatch. (2022) (0)
From the pages of AllergyWatch September 2021 (0)
Efficacy and Safety of Itepekimab in Patients With Moderate-to-Severe Asthma (2022) (0)
From the pages of AllergyWatch. (2020) (0)
Poster Session4200Monday, March 21, 20059:45 AM to 10:45 AMVariability in asthma severity in pediatric asthma patients previously receiving short-acting beta2-agonists (2005) (0)
From the Pages of AllergyWatch. (2022) (0)
Continuous Positive Airway Pressure in Hemidiaphragmatic Paralysis (1981) (0)
Maintenance Systemic Corticosteroid Use Is Associated with Multiple Adverse Conditions in U.S. Adults with Severe Asthma: Results from the Chronicle Study (2020) (0)
Effects of Doubling the Highest Indicated Dose of Budesonide/Formoterol (BUD/FM) on Lung Function and Symptoms in Moderate-to-Severe Asthma with Fixed Airflow Obstruction (FAO) (2015) (0)
Long-Term Use of Maintenance Systemic Corticosteroids is Associated with Multiple Adverse Conditions in a Large, Real-World Cohort of US Adults with Severe Asthma (2022) (0)
Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by exacerbations in previous year and maintenance use of OCS (2020) (0)
P065 DISEASE TRIGGERS AND ASSOCIATED QUALITY OF LIFE AMONG SPECIALIST-TREATED US PATIENTS WITH SEVERE ASTHMA (2021) (0)
P236 Comorbidities associated with poor short-acting beta-agonist inhaler handling among united states respiratory patients (2017) (0)
Not running on empty. Auhtors' reply (2006) (0)
Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the Tenor II Cohort (2016) (0)
From the Pages of Allergy Watch. (2020) (0)
Preferences in Terminology Used to Describe Oral Immunotherapy Varies Based on Physician Utilization: 810 (2019) (0)
BIOLOGIC MEDICATION USE AND SWITCHING AMONG REAL-WORLD, SPECIALIST-TREATED ADULTS WITH SEVERE ASTHMA: RESULTS OF THE CHRONICLE STUDY (2020) (0)
Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ) and Patient Perception of Disease Status, Health-Related Quality of Life, and Treatment Adherence (2023) (0)
Assessment of asthma morbidity by US patients, specialists, Asthma Control Test™, and Asthma Impairment and Risk Questionnaire™ (2020) (0)
Asthma Control and Study Withdrawal in Patients With Versus Without Fixed Airflow Obstruction (2 Criteria): Post Hoc Analysis of a Budesonide/Formoterol Pressurized Metered-Dose Inhaler Study in Patients With Moderate to Severe Asthma (2012) (0)
SIGNIFICANT IMPROVEMENT IN LUNG FUNCTION FOLLOWING 16 WEEKS OF OMALIZUMAB TREATMENT: POOLED ANALYSES IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA (2018) (0)
CLASSIFICATION OF ASTHMA SEVERITY AMONG STEROID-NAÏVE PEDIATRIC SUBJECTS PREVIOUSLY RECEIVING SHORT-ACTING BETA2-AGONISTS: DO THE GUIDELINES NEED REVISITING? (2005) (0)
From the Pages of AllergyWatch. (2022) (0)
Effect of Fixed Airflow Obstruction (FAO) Status on Lung Function, Asthma Control Days (ACD), and Asthma Symptom Score (AS) Responses to Budesonide/Formoterol (BUD/FM) Treatment in Patients with Moderate-to-Severe Asthma (2015) (0)
Environmental factors theophylline level and pulmonary function in asthmatics (1979) (0)
How Do Rates of Asthma Exacerbations Compare in Pediatric and Adult Patients in TENOR (2009) (0)
Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) in African-American Patients with Moderate to Severe Asthma: Responder Analysis in Patients with Versus without Fixed Airflow Obstruction (FAO) (2013) (0)
From the pages of AllergyWatch® (2021) (0)
COMPARISON OF ASTHMA CONTROL AND TREATMENT EFFECTIVENESS ASSESSMENTS BETWEEN US PATIENTS WITH ASTHMA AND TREATING SUBSPECIALISTS: REAL-WORLD DATA FROM THE CHRONICLE STUDY (2019) (0)
Spirometry versus flow volume inspiratory and expiratory loop. (2011) (0)
DOES ASTHMA OR TREATMENT WITH THEOPHYLLINE LIMIT CHILDREN'S ACADEMIC PERFORMANCE? (1994) (0)
From the pages of AllergyWatch®: November 2020. (2020) (0)
Expert Advice on Managing Severe Asthma: An Interactive Decision Support Tool Provides Real-Time Expert Recommendations (2021) (0)
Acute asthma. (1986) (0)
P204 FACTORS ASSOCIATED WITH BIOLOGIC OR MAINTENANCE SYSTEMIC CORTICOSTEROID TREATMENT AMONG UNITED STATES SEVERE ASTHMA PATIENTS (2019) (0)
A Synopsis of the Synopses (2007) (0)
Research abstracts presented at the Western Society of Allergy, Asthma, and Immunology Meeting, January 24‐28, 2010 (2010) (0)
Asthma & Other Lung Diseases/Allergy Testing & Therapeutics/Rhinosinusitis/Ocular Allergy (2018) (0)
From Pages of Allergy Watch-March 2020. (2019) (0)
P146 Influence of inhalation technique on lung deposition using flunisolide HFA, fluticasone HFA and beclomethasone HFA (2016) (0)
Biologic Use and Outcomes Among Adults with Severe Asthma Treated by United States Subspecialists. (2022) (0)
RESPONSE TO OMALIZUMAB TREATMENT IN PATIENTS WITH FIXED AIRFLOW OBSTRUCTION (2019) (0)
Helen Skolnick SPECIALTY CARE KNOWLEDGE AND PRACTICE OF DUST MITE CONTROL BY Services (0)
Determinants of Lung Function Decline in Children and Adolescents With Severe Asthma (2017) (0)
Management of acute bronchospasm in pediatric populations. (2005) (0)
Reply. (2019) (0)
Effects of Sex and Age on Characteristics of United States Patients With Severe Asthma (2021) (0)
Reply to Dr. Bisgaard. (2004) (0)
Control your child's asthma. By Harold Farber. Henry Holt, 2000, 231 pp. (2002) (0)
Section on Allergy and Immunology (2007) (0)
The Association Of Exacerbations With Quality Of Life In Children With Severe-or-Difficult To Treat Asthma (2010) (0)
ACCURACY OF MINI PEAK-FLOW METERS (PFMS) IN INDICATING CHANGES IN LUNG FUNCTION IN CHILDREN WITH ASTHMA (1995) (0)
ATTITUDES AMONG U.S.-BASED ALLERGISTS AND IMMUNOLOGISTS ABOUT IMMUNOTHERAPY, PEANUT EXPOSURE AND TREATMENT (2018) (0)
Effect Of Fixed Airflow Obstruction On Response To Budesonide/Formoterol Pressurized Metered-Dose Inhaler Treatment In African-American Adolescents And Adults With Moderate To Severe Asthma (2012) (0)
O020 Asthma exacerbations and lung function decline in children during a 52-week controlled trial of omalizumab (2016) (0)
The Evolution of Childhood Wheezing to Asthma (2014) (0)
From the Pages of Allergy Watch. (2021) (0)
Albuterol-budesonide pressurized metered dose inhaler in patients with mild-to-moderate asthma: results of the DENALI double-blind randomized controlled trial. (2023) (0)
Effect Of Budesonide/Formoterol Pressurized Metered-Dose Inhaler On Pulmonary Function In Hispanic Adolescents And Adults With Moderate To Severe Asthma With Or Without Fixed Airflow Obstruction (2012) (0)
Treatment Response To Omalizumab And Reduced Asthma Exacerbations And Asthma-Related Healthcare Resource Use From The Real-World PROSPERO Study (2020) (0)
Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles (2020) (0)
From the Pages of Allergy Watch. (2021) (0)
Are PPIs beneficial for nasal polyps? (2019) (0)
Faculty Opinions recommendation of Abnormal vocal cord function in difficult-to-treat asthma. (2011) (0)
Treatment of Acute Asthma (2011) (0)
From the Pages of Allergy Watch. (2022) (0)
Baseline Characteristics Associated with Quartiles of Reslizumab Effect: Pooled Analysis Of Two Phase 3 Studies (2018) (0)
Oral Corticosteroid Use and Health Outcomes in Patients with Severe or Difficult-to-Treat Asthma (2015) (0)
Asthma Diagnosis and Biomarkers (2016) (0)
Biologics for Asthma and Allergic Skin Diseases in Children. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bradley E. Chipps?

Bradley E. Chipps is affiliated with the following schools:

University of Texas Medical Branch